Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Autor: Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu

Publikováno v: Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)

Abstract Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized con

Externí odkaz: https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922e

Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer

Autor: Jingru Yang, Mingliang Deng, Minghong Bi, Yaping Wang, Xuxu Qiao, Shanshan Zhang

Publikováno v: Future Science OA, Vol 8, Iss 5 (2022)

Purpose: Inflammatory indexes, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and lymphocyte-to-monocyte ratio (LMR), have been confirmed as prognostic factors in multiple

Externí odkaz: https://doaj.org/article/b386e89212ac4038ab58e1193cc6f201

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

Autor: Yuankai, Shi, Shiman, Wu, Ke, Wang, Shundong, Cang, Wenxiu, Yao, Yun, Fan, Lin, Wu, Meijuan, Huang, Xingya, Li, Yueyin, Pan, Zhixiong, Yang, Bo, Zhu, Gongyan, Chen, Jianhua, Shi, Meili, Sun, Jian, Fang, Lijun, Wang, Zhaohong, Chen, Chunling, Liu, Jingzhang, Li, Jiwei, Liu, Shenghua, Sun, Yanqiu, Zhao, Yanzhen, Guo, Zili, Meng, Zhefeng, Liu, Zhigang, Han, Hong, Lu, Rui, Ma, Sheng, Hu, Guofang, Zhao, Zheng, Liu, Congying, Xie, Diansheng, Zhong, Hui, Zhao, Huiqing, Yu, Longzhen, Zhang, Minghong, Bi, Shanyong, Yi, Shuliang, Guo, Tienan, Yi, Wen, Li, Yingcheng, Lin, Yongqian, Shu, Zhendong, Chen, Zhongliang, Guo, Michael, Greco, Tingting, Wang, Haijiao, Shen

Publikováno v: Journal of Thoracic Oncology. 17:1306-1317

Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFR T790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff897beef424629d3b564488086dc315
https://doi.org/10.1016/j.jtho.2022.08.015

Supplementary Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study

Autor: Chao Gao, Qian Guo, Chunmei Shi, Zhiwei Tao, Hongyan Ying, Guowen Wang, Yuhong Zhou, Baocheng Wang, Minghong Bi, Gang Huang, Yu Jiang, Qiqing Cai, Yuankai Shi

supplementary data-tracking

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94b8f07f4a52b50cc0367b08c7bbcdad
https://doi.org/10.1158/1078-0432.22477136

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Autor: Zhongliang Guo, Jian Fang, Junhong Zhang, Puyuan Xing, Xiaoli Zhu, Changlu Hu, Yuming Jia, Ming Zhou, Zhiwei Lu, Bin Wang, Ke Wang, Yiping Zhang, Lin Wu, Zhanyu Pan, Yanju Chen, Junquan Yang, Shuhua Han, Yongqian Shu, Lianke Liu, Bingqiang Ni, Yong Liu, Hongming Pan, Rongyu Liu, Shengming Liu, Qian Sun, Feng Ye, Qinhong Zheng, Guojun Zhang, Tiegang Tang, Tianjiang Ma, Jianyong Zhang, Bo Jiang, Mafei Kang, Zhiguo Luo, Wenjuan Lian, Can Wu, Lijun Ma, Zhiyong He, Wensheng Qiu, Dongqing Lv, Zheng Liu, Qisen Guo, Dedong Wu, Ke Xiao, Xia Yuan, Jun Chen, Yan Yu, Yuankai Shi, Guolei Wang, Dongji Chen, Shuyang Zhu, Jianhua Shi, Guolong Liu, Hua Zhang, Hongbing Duan, Bo Qiu, Wangjun Liao, Shumin Wang, Jinsheng Shi, Tienan Yi, Hong Lu, Xueli Yuan, Emei Gao, Yimin Mao, Xicheng Wang, Li Zhao, Xiaohong Wu, Yanqiu Zhao, Yan Wang, Kaijian Lei, Yinghua Ji, Yulong Zheng, Minghong Bi, Manxiang Li, Debin Sun, Yuan Chen

Publikováno v: Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)
Cancer Communications

Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df18b6bb21c6add27ccbf366193128e
https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922e